End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.61 USD | +4.40% | -4.17% | +107.79% |
16/05 | HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target | MT |
10/05 | Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating | MT |
Sales 2024 * | 1.82M 152M | Sales 2025 * | 1.98M 165M | Capitalization | 634M 52.9B |
---|---|---|---|---|---|
Net income 2024 * | -63M -5.25B | Net income 2025 * | -88M -7.34B | EV / Sales 2024 * | 176 x |
Net cash position 2024 * | 314M 26.15B | Net cash position 2025 * | 518M 43.25B | EV / Sales 2025 * | 58.5 x |
P/E ratio 2024 * |
-9.85
x | P/E ratio 2025 * |
-8.31
x | Employees | 53 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.16% |
1 day | +4.40% | ||
1 week | -4.17% | ||
1 month | -4.08% | ||
3 months | -16.08% | ||
6 months | +91.75% | ||
Current year | +107.79% |
Date | Price | Change | Volume |
---|---|---|---|
31/24/31 | 21.61 | +4.40% | 229,868 |
30/24/30 | 20.7 | -6.59% | 154,451 |
29/24/29 | 22.16 | +1.09% | 58,780 |
28/24/28 | 21.92 | -2.79% | 122,870 |
24/24/24 | 22.55 | +3.58% | 122,810 |
End-of-day quote Nasdaq, May 31, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+107.79% | 634M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- DNTH Stock